Generation Bio
Edit info- Founded: 2017
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin0
- Therapy area: Hemophilia A
- Drug types: GEN, HEM, OPH, GER, VAC, HEP, PED
- Lead product: Undisclosed
- Funding: $230M IPO Jun 2020; $110M C Jan 2020; $100M B Feb 2018; $25M A Jan 2018
generationbio.com linkedin.com job board
Drug notes:
7 undisclosed programs RD PKU, Wilson disease, Gaucher disease, Leber congenital amaurosis 10, Stargardt disease, wet AMD, ETAP
About:
Generation Bio is developing a new class of genetic medicines. Using their proprietary non-viral genetic medicine platform, Generation Bio is creating scalable and redosable medicines. The platform uses closed-ended DNA (ceDNA) encased in cell-targeted lipid nanoparticles. ceDNA has 3x the carrying capacity of AAV capsids and has the potential to offer durable expression. The medicines designed by Generation Bio are efficiently manufactured - ceDNA can be consistently produced with high purity using their cell-free rapid enzymatic synthesis approach. Generation Bio is building a portfolio initially targeting diseases of the liver and retina before expanding into skeletal muscle and the CNS.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com